KEYNOTE-199 is a multi-cohort trial of the PD-1 inhibitor pembrolizumab in men with metastatic castration-resistant prostate cancer.
Results from cohorts 1–3, which comprised individuals previously treated with docetaxel receiving pembrolizumab monotherapy, have already been reported.
The results for the remaining cohorts, 4 and 5, composed of enzalutamide-resistant patients receiving pembrolizumab added to enzalutamide were presented at ASCO GU 2020 by Dr Julie Graff (Oregon Health and Science University, Portland, USA). The results showed that the combination provides durable responses and a manageable safety profile.